Lilly Announced Nearly 80% Of Patients With Moderate-to-severe Atopic Dermatitis Maintained Clear Or Almost Clear Skin With Lebrikizumab Monthly Maintenance Dosing At Two Years
Portfolio Pulse from Charles Gross
Eli Lilly and Company (LLY) announced that nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with lebrikizumab monthly maintenance dosing at two years. The results from the ADjoin long-term extension study will be presented at the 43rd Annual Fall Clinical Dermatology Conference.
October 20, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's lebrikizumab shows promising long-term results for treating atopic dermatitis, which could potentially boost the company's market position in dermatological treatments.
The positive long-term results of lebrikizumab treatment for atopic dermatitis could potentially increase Eli Lilly's market share in dermatological treatments. This could lead to increased revenues and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100